GlassScriptPhysician profile
Rachel E Reed
NPI 1417145293
$2,035.77
in general payments reported to CMS, 2019-2025
24 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $465 · 2023: $350 · 2024: $525 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $262.16 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $240.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $236.83 | 2021-2025 | |
| Lilly USA, LLC | $206.32 | 2021-2025 | Emgality, Reyvow, Zepbound |
| Amgen INC. | $167.24 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $145.09 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $122.93 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $107.59 | 2022-2025 | Gardasil 9, Dificid, Capvaxive |
| Lundbeck LLC | $69.50 | 2023-2025 | Rexulti |
| Abbott Laboratories | $63.48 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.01 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $52.91 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $43.18 | 2022-2025 | Trintellix |
| Almatica Pharma LLC | $41.96 | 2022 | |
| Boston Scientific Corporation | $40.16 | 2023-2025 | Wavewriter Alpha Prime 16 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.78 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $27.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.40 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $17.29 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $16.35 | 2022 | |
| Eisai INC. | $15.74 | 2025 | |
| Intra-Sana Laboratories | $14.88 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Axsome Therapeutics, INC. | $13.38 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.